Collabrium Partners Advised Swedish LinkoCare Life Sciences AB on Its Capital Financing From a Select Asian Investor
February 6, 2024 at 5:13:40 AM
Linköping Sweden, Hong Kong SAR – February 2, 2024. LinkoCare Life Sciences AB announced that it has completed a new round of fund-raising activity from a select Asian investor from Hong Kong. LinkoCare is a Swedish knowledge-intensive bioengineering company developing innovative medical devices for sight restoration. The company’s vision is to provide society with natural, high-quality, reliable, cost-effective bio-engineered corneal implants that meet the huge demand of the world population suffering from corneal blindness and low vision. LinkoCare corneal implants can be used both for patients with corneal blindness who need a full-thickness implant and for those who suffer from corneal vision impairment and need a partial-thickness implant. LinkoCare bio-engineered implants will capture a significant share of the market for corneal blindness and low vision due to their advanced functionality, safety, cost-effectiveness, and long-term durability over existing solutions such as human donor corneas, the prosthetic artificial corneas, and synthetic inter-corneal lenses.
Dr. Mehrdad Rafat, Founder & CEO of LinkoCare Life Sciences commented, “We are very happy to work with Collabrium Partners to bring in selective investors to our company and expand our business into the Asian region. This is a great opportunity for us to continue building our technology platform for product registration and mass production, taking it to the next level.”
Adam Zhang, Founding Partner and CEO of Collabrium Partners, further commented, “We are pleased to have advised LinkoCare Life Sciences on its recent fundraising from a select Asian investor. We are impressed by the company’s unwavering commitment to research and development of cutting-edge technology that aims to improve vision, patient care, and life quality for millions of people worldwide suffering from corneal blindness and low vision. This is yet another milestone that demonstrates Collabrium Partners’ strong network and capability in the healthcare and technology sectors.”
LinkoCare is a company headquartered in Linköping, Sweden, which was founded in 2014 and originated from academic research in Canada and Sweden. The company has developed two major platforms, CorVision® and LinkCor®. CorVision® is a natural corneal microlens made of collagen, the same material as the human cornea. The microlens integrate with the corneal environment long-term and avoid biocompatibility, haze, and interface issues associated with other microlenses. It eliminates the need for reading spectacles, contact lenses, or more invasive surgeries such as LASIK. LinkCor® is a bioengineered corneal implant for the treatment of corneal blindness caused by diseases such as keratoconus, corneal dystrophy, and corneal scarring. Partial thickness inter-corneal implants are also available for sight correction in patients with low vision.
- Collabrium Partners News -
About Collabrium Partners
Collabrium Partners is a Chinese leading independent investment banking firm focused on providing financial advisories on mergers & acquisitions, strategic planning, restructuring, private placement, independent opinions to corporations, financial institutions, public service agencies, and others.
For more information, please visit www.collabrium.com